Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

Not Yet Recruiting NCT07671092

Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC

Conditions: Metastatic Urothelial Carcinoma, Breast Cancer, TNBC - Triple-Negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, NSCLC

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Phase: EARLY_PHASE1

Enrollment: 40

Sponsor: RayzeBio, Inc.

Location: Research Facility Christchurch

Summary

This imaging study aims to assess the feasibility, biodistribution, and dosimetry of the imaging agent in subjects with metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC.

Eligibility Criteria

Inclusion Criteria: * Are at least 18 years old at the time of signing the informed consent form (ICF) * Have biopsy proven metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC Exclusion Criteria: * For Women of Childbearing Potential: Are pregnant or breastfeeding Note: Additional criteria may apply and will be assessed by the study site

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07671092). StuddyBuddy aggregates publicly available trial information.